

# Aggressive Lymphoma Workshop

Bologna, Royal Hotel Carlton  
May 8-9, 2023


## Genomic classification of DLBCL

**Roland Schmitz, Ph.D.**  
Justus Liebig University Giessen

President: **Pier Luigi Zinzani**





# Dissecting Cancer Into Molecularly and Clinically Distinct Subtypes by Gene Expression Profiling




# Dissecting Cancer Into Molecularly and Clinically Distinct Subtypes by Gene Expression Profiling

Diffuse Large B Cell  
Lymphoma  
(DLBCL)




Subtype-specific response  
To chemotherapy

# Building a Genetic Classification of DLBCL




# Extensive Genetic Differences Between ABC and GCB DLBCL




Genetic aberrations

Schmitz et al. NEJM 2018

# Defining ABC, GCB and Unclassified DLBCL Based on the ABC/GCB predictor score




# Heterogeneity of Genetic Aberrations Within DLBCL Gene Expression Subgroups







# Building a Genetic Classification of DLBCL




# Genetic Subtypes of Diffuse Large B cell Lymphoma



# Genetic Subtypes of Diffuse Large B cell Lymphoma









Chapuy et al. Nat. Med. 2018



Lacy et al. Blood 2020

# Genetic Subtypes of Diffuse Large B cell Lymphoma




**Genetic alteration**

- Missense mutation
- Truncating mutation
- Inframe mutation
- Fusion
- Amplification
- Gain
- Homozygous deletion
- Heterozygous deletion


**Gene expression subgroup**

- ABC
- GCB
- Unclassified


# Relationship between DLBCL COO Subgroups and Genetic Subtypes





# The MCD Genetic Subtype of DLBCL



# Similarities of MCD DLBCL to Extranodal DLBCL




# Similarities of MCD DLBCL to Extranodal DLBCL







# The A53 Genetic Subtype of DLBCL




# The BN2 Genetic Subtype of DLBCL




# Genetic Relationship Between BN2 DLBCL and Marginal Zone Lymphomas




# Genetic Relationship Between BN2 DLBCL and Marginal Zone Lymphomas




# The ST2 Genetic Subtype of DLBCL




# Genetic Relationship Between ST2 DLBCL and T cell/histiocyte-rich large B cell lymphoma / Hodgkin Lymphoma



# The EZB Genetic Subtype of DLBCL





# Genetic Relationship Between EZB DLBCL and Follicular Lymphomas









# DLBCL Genetic Subtype Predict Survival Following R-CHOP



# DLBCL Genetic Subtype Predict Survival Following R-CHOP



# DLBCL Genetic Subtype Predict Survival Following R-CHOP



# Genetic Subgroups of Diffuse Large B cell Lymphoma









# Genetic Subgroups of Diffuse Large B cell Lymphoma















## Hallmark genetic features

<b>MCD</b>	MyD88 L265P / CD79B HLA CDKN2A
<b>N1</b>	NOTCH1
<b>A53</b>	TP53 inactivation aneuploidy
<b>BN2</b>	NOTCH2 BCL6 transloc. TNFAIP3
<b>ST2</b>	PI3K JAK / STAT
<b>EZB</b>	BCL2 transloc. EZH2 PI3K CREBBP / EP300


# Genetic Subgroups of Diffuse Large B cell Lymphoma

	Hallmark genetic features	Genetically similar lymphomas
	MyD88 L265P / CD79B HLA CDKN2A	Prim. Extranodal DLBCL
	NOTCH1	CLL
	TP53 inactivation aneuploidy	-
	NOTCH2 BCL6 transloc. TNFAIP3	MZL
	PI3K JAK / STAT	THCR LBCL HL
	BCL2 transloc. EZH2 PI3K CREBBP / EP300	FL tFL BL

# Genetic Subgroups of Diffuse Large B cell Lymphoma


	Hallmark genetic features	Genetically similar lymphomas	Drug target					
			BTK	PI3K	BCL2	JAK	IRF4	EZH2
<b>MCD</b>	MyD88 L265P / CD79B HLA CDKN2A	Prim. Extranodal DLBCL						
<b>N1</b>	NOTCH1	CLL						
<b>A53</b>	TP53 inactivation aneuploidy	-						
<b>BN2</b>	NOTCH2 BCL6 transloc. TNFAIP3	MZL						
<b>ST2</b>	PI3K JAK / STAT	THCR LBCL HL						
<b>EZB</b>	BCL2 transloc. EZH2 PI3K CREBBP / EP300	FL tFL BL						

# Genetic Subclassification in a “Real-World” Analysis






# Cell of Origin Classification Using Mutation Profiling






# Cell of Origin Classification Using Mutation Profiling


## Hans classifier




## Genetic COO classifier





# Genetic Subgroups using Whole Exome Seq and Panel Seq




All DLBCL  
(N=93)




# Genetic Subgroups using Whole Exome Seq and Panel Seq



# Similar Composition of DLBCL Cohorts




NCI cohort  
N=574



study cohort  
N=206

# DLBCL Genetic Subtype Predict Survival Following R-CHOP



# Genetic Subgroups of Diffuse Large B cell Lymphoma

MCD

N1

A53

BN2

ST2

EZB

1. DLBCL is genetically very heterogeneous
2. Comprehensive, multi-platform genomic analysis reveals at least 6 genetic subtypes of DLBCL
3. DLBCL genetic subtypes reveal genetic relationships with other lymphoma types point towards an origin from occult indolent lymphomas
4. The response to R-CHOP therapy is influenced by the DLBCL genetic subtype distinction
5. Precision medicine approaches should take into account both the DLBCL genetic subtypes AND genetic aberrations in oncogenic pathways

# Acknowledgements

National Cancer  
Institute

---

Da Wei Huang  
George Wright  
Calvin Johnson

Stefania Pittaluga  
Lou Staudt

Members of the  
LLMPP Consortium

---

Alliance  
Cooperative Group  
Nancy Bartlett  
John Leonard  
Andy Zelenetz

Department of Pathology  
University of Giessen

---

Frederike Hagedorn  
Hung Dang  
Nicolai Fuhr

Andreas Bräuninger  
Stefan Gattenlöhner

Hematology Department  
University of Giessen

---

Tobias Arnold  
Felix Schell

Mathias Rummel